Allison Sumis

Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase

Open-label add-on treatment trial of minocycline in fragile X syndrome

The role of fragile X mental retardation protein in major mental disorders

Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1

The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome

Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases

DNA Methylation and Its Basic Function

Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach

From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis

Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism

Therapeutic Potential of Mood Stabilizers Lithium and Valproic Acid: Beyond Bipolar Disorder

Structural Bases of Desensitization in AMPA Receptor-Auxiliary Subunit Complexes

Elucidation of AMPA receptor–stargazin complexes by cryo–electron microscopy

Minocycline: far beyond an antibiotic

Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome

Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome